专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004037809A1 TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA 审中-公开
标题翻译：三唑类化合物用于治疗脑损伤
公开(公告)号：WO2004037809A1
公开(公告)日：2004-05-06
申请号：PCT/IB2003/004587
申请日：2003-10-14
申请人： PFIZER LIMITED , PFIZER INC. , ARMOUR, Robert, Duncan , BAXTER, Andrew, Douglas , BRYANS, Justin, Stephen , DACK, Kevin, Neil , JOHNSON, Patrick, Stephen , LEWTHWAITE, Russell, Andrew , NEWMAN, Julie , RAWSON, David, James , RYCKMANS, Thomas
发明人： ARMOUR, Robert, Duncan , BAXTER, Andrew, Douglas , BRYANS, Justin, Stephen , DACK, Kevin, Neil , JOHNSON, Patrick, Stephen , LEWTHWAITE, Russell, Andrew , NEWMAN, Julie , RAWSON, David, James , RYCKMANS, Thomas
IPC分类号： C07D401/04
CPC分类号： C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/04 , C07D413/06 , C07D413/14
摘要： A compound of formula (I), a pharmaceutically acceptable salt or solvate thereof, wherein R' represents C,-C6 alkyl, -(CH 2 ) c -[C 3 -C 8 cycloalkyl]-, -(CH 2 ) C -W or -(CH 2 ) C -Z-(CH 2 ) d W; W represents C 1 -C 6 alkyl, C 1 -C 6 alkyloxy, -C0 2 [C 1 -C 6 alkyl], -CONR 4 R 5 , an optionally substituted phenyl group, NR 4 R 5 , het 2 or het 3 ; Z represents O or S(O) g ; g represents 0, 1 or 2; R 2 represents a phenyl group, optionally fused to a 5- or 6- membered aryl or heterocyclic group which may contain one or more heteroatoms selected from N, O or S; the phenyl group and the optionally fused group being optionally substituted; Ring A represents a 4-, 5- or 6- membered saturated heterocyclic group containing at least one N; Ring B represents a phenyl group or het 1 , each group being optionally substituted; R 7 independently represents H 1 C 1 -C 6 alkyl, OR 3 , -(CH 2 ) e -R 3 or -(CH 2 ) f -O-(CH 2 ) e -R 3 ; at each occurrence R 3 independently represents H 1 C 1 -C 6 alkyl optionally substituted by Y, -(CH 2 ) g [C 3 -C 8 cycloalkyl], phenyl, benzyl, pyridyl or pyrimidyl; at each occurrence R 4 and R 5 independently represent H 1 C l -C 6 alkyl (optionally substituted with C l -C 6 alkyloxy), (CH 2 ) g C0 2 -[C 1 -C 6 alkyl], -S0 2 Me, -(CH 2 ) g [C 3 -C 8 cycloalkyl], S0 2 Me, phenyl, benzyl, pyridyl or pyrimidyl; or R 4 and R 5 together with the N atom to which they are attached represent a heterocyclic group of from 3 to 8 atoms; Y independently represents a phenyl group, NR 4 R 5 or het 4 , the phenyl group being optionally substituted; het 1 represents a 4-, 5- or 6- membered saturated, or unsaturated, heterocyclic group containing at least one N (but which may also contain one or more O or S atoms); het 2 and het 4 represent an optionally substituted 4-, 5-, 6- or 7- membered saturated, or unsaturated, heterocyclic group containing at least one N (but which may 5 also contain one or more O or S atoms); het3 represents an optionally substituted 4-, 5-, 6- or 7- membered saturated, or unsaturated, heterocyclic group containing at least one O (but which may also contain one or mare N or S atoms); at each occurrence R 6 independently represents H 1 C 1 -C 6 alkyl optionally substituted by Y, =(CH 2 ) g [C 3 -C 8 cycloalkyl], phenyl, benzyl, pyridyl or pyrimidyl; a and b independently represent 0 or 1; c,, d, a end g independently represent 0, 1, 2, 3 or 4; . f índeperldently represents 1, 2, 3 or 4; provided that: (i) a + b cannot equal 0; and províded,that,when R 1 represents -(CH 2 ) c -Z-(CH 2 ) d -W and W represents.NR 4 R 5 or any N linked heterocyclic, group then d must not be, 0 or 1; and (iii), provided that when R 2 represents a phenyl group substituted by a group of, formula -(CH 2 ) e OR 3 , -(CH 2 ) e -OCOR 3 or -(CH 2 ) e ,OCOR 3 ;or het 1 ,and/or het 2 are substituted by a group of formula -(CH 2 ) e OR 3 , (CH 2 ),-CO 2 R 3 or -(CH 2 ) e OCOR 3 ; or when R 7 represents -OR 3 or -(CH 2 ) f -0-(CH 2 ) e -R 3 and e is 0; or when W represents a phenyl group substituted with -OR 3 or - C0 2 R 3 and R 3 represents an alkyl group substituted with Y, and Y represents NR 4 R 5 or an N-Finked het 3 ; then, R 3 , must,represent,C 2 -C 6 alkyl substituted with. Y. are useful in the treatment of dysmenorrhoea.
摘要翻译：式（I）化合物，其药学上可接受的盐或溶剂化物，其中R'表示C 1-6烷基， - （CH 2）c - [C 3 -C 8环烷基] - ， - （CH 2）C-W或 - （ CH2）CZ-（CH 2）一页; W表示C1-C6烷基，C1-C6烷氧基，-CO2 [C1-C6烷基]，-CONR4R5，任选取代的苯基，NR4R5，het2，或het <3>; Z表示O或S（O）g; g表示0,1或2; R 2表示苯基，任选地与可含有一个或多个选自N，O或S的杂原子的5-或6-元芳基或杂环基稠合; 苯基和任选稠合基团任选被取代; 环A表示含有至少一个N的4-，5-或6-元饱和杂环基; 环B表示苯基或het 1，每个基团任选被取代; R 7独立地表示H 1 C 1 -C 6烷基，OR 3， - （CH 2）e -R 3或 - （CH 2）f -O-（CH 2）e -R 3; 在每次出现时，R 3独立地表示任选被Y， - （CH 2）g [C 3 -C 8环烷基]，苯基，苄基，吡啶基或嘧啶基取代的H 1 C 1 -C 6烷基; 在每次出现时，R 4和R 5独立地表示H 1 C 1 -C 6烷基（任选被C 1 -C 6烷氧基取代），（CH 2）g CO 2 - [C 1 -C 6烷基]，-SO 2 Me， - （CH 2） C 3 -C 8环烷基]，SO 2 Me，苯基，苄基，吡啶基或嘧啶基; 或R 4和R 5与它们所连接的N原子一起表示3至8个原子的杂环基; Y独立地表示苯基，NR4R5或het4，苯基任选被取代; 表示含有至少一个N（但也可含有一个或多个O或S原子）的4-，5-或6-元饱和或不饱和杂环基; het 2和het 4代表任选被取代的含有至少一个N（但也可以含有一个或多个O或S的N，R 5，R 6，原子）; het3表示含有至少一个O（但也可含有一个或多个N或S原子）的任选取代的4-，5-，6-或7-元饱和或不饱和杂环基; 在每次出现时，R 6独立地表示任选被Y，=（CH 2）g [C 3 -C 8环烷基]，苯基，苄基，吡啶基或嘧啶基取代的H 1 C 1 -C 6烷基; a和b独立地表示0或1; c，d，末端g独立地表示0,1,2,3或4; 。 f，并且代表1,2,3或4; 条件是：（i）a + b不能等于0; 并证明当R 1表示 - （CH 2）c

2. 发明申请

WO2004016583A1 SUBSTITUTED GLYCINE DERIVATIVES FOR USE AS MEDICAMENTS 审中-公开
标题翻译：用作药物的取代的甘氨酸衍生物
公开(公告)号：WO2004016583A1
公开(公告)日：2004-02-26
申请号：PCT/IB2003/003708
申请日：2003-08-04
申请人： PFIZER LIMITED , PFIZER INC. , BLAKEMORE, David, Clive , BRYANS, Justin, Stephen , MAW, Graham, Nigel , RAWSON, David, James , THOMPSON, Lisa, Rosemary , CHU, Wai-Lam, Alexis
发明人： BLAKEMORE, David, Clive , BRYANS, Justin, Stephen , MAW, Graham, Nigel , RAWSON, David, James , THOMPSON, Lisa, Rosemary , CHU, Wai-Lam, Alexis
IPC分类号： C07C323/25
CPC分类号： C07C323/25 , A61K31/198 , A61K31/223 , A61K31/47 , C07C229/12 , C07C229/14 , C07C323/32 , C07D217/02
摘要： The compounds of formula (I) are substituted glycine derivatives useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, arthritis, neuropathological disorders, sleep disorders, visceral pain disorders and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included. Formula (I) wherein R' is hydroxycarbonyl, a carboxylic acid biostere or prodrug thereof; R 3 , R 3a , R 2 and R 2a are independently selected from H, C 1 -C 6 alkyl, and C l -C 6 alkoxy C l -C 6 alkyl.
摘要翻译：式（I）化合物是用于治疗癫痫，微弱发作，运动功能减退，颅内疾病，神经变性障碍，抑郁症，焦虑症，恐慌症，疼痛，关节炎，神经病理学障碍，睡眠障碍，内脏疼痛障碍和胃肠道的取代甘氨酸衍生物障碍。包括用于制备在该方法中有用的最终产物和中间体的方法。还包括含有一种或多种化合物的药物组合物。式（I）其中R'是羟基羰基，羧酸生物降解剂或其前药; R 3，R 3a，R 2和R 2a独立地选自H，C 1 -C 6烷基和C 1 -C 6烷氧基C 1 -C 6烷基。

3. 发明申请

WO2012007883A1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN 审中-公开
标题翻译：作为NAV1.7的磺胺衍生物用于治疗疼痛的抑制剂
公开(公告)号：WO2012007883A1
公开(公告)日：2012-01-19
申请号：PCT/IB2011/053030
申请日：2011-07-07
申请人： PFIZER LIMITED , BELL, Andrew, Simon , BROWN, Alan, Daniel , DE GROOT, Marcel, John , LEWTHWAITE, Russell, Andrew , MARSH, Ian, Roger , MILLAN, David, Simon , PEREZ PACHECO, Manuel , RAWSON, David, James , SCIAMMETTA, Nunzio , STORER, Robert, Ian , STUPPLE, Paul, Anthony , SWAIN, Nigel, Alan
发明人： BELL, Andrew, Simon , BROWN, Alan, Daniel , DE GROOT, Marcel, John , LEWTHWAITE, Russell, Andrew , MARSH, Ian, Roger , MILLAN, David, Simon , PEREZ PACHECO, Manuel , RAWSON, David, James , SCIAMMETTA, Nunzio , STORER, Robert, Ian , STUPPLE, Paul, Anthony , SWAIN, Nigel, Alan
IPC分类号： C07C311/00 , A61P29/00
CPC分类号： C07C311/51 , C07C2601/02 , C07D231/12 , C07D233/60 , C07D237/08
摘要： The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I):or a pharmaceutically acceptable salt thereof, wherein Ar 1 , X, R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.
摘要翻译：本发明涉及磺酰胺衍生物，其在医学上的用途，含有它们的组合物，其制备方法以及在这些方法中使用的中间体。更具体地，本发明涉及式（I）的新的磺酰胺Nav1.7抑制剂：或其药学上可接受的盐，其中Ar1，X，R1，R2，R3，R4和R5如说明书中所定义。 Nav 1.7抑制剂可用于治疗各种疾病，特别是疼痛。

4. 发明申请

WO2012007861A1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS 审中-公开
标题翻译： N-磺酰苯胺衍生物作为电压门式通道抑制剂有用
公开(公告)号：WO2012007861A1
公开(公告)日：2012-01-19
申请号：PCT/IB2011/052797
申请日：2011-06-24
申请人： PFIZER LIMITED , BELL, Andrew, Simon , BROWN, Alan, Daniel , DE GROOT, Marcel, John , GAULIER, Steven, Matthieu , LEWTHWAITE, Russell, Andrew , MARSH, Ian, Roger , MILLAN, David, Simon , PEREZ PACHECO, Manuel , RAWSON, David, James , SCIAMMETTA, Nunzio , STORER, Robert, Ian , SWAIN, Nigel, Alan
发明人： BELL, Andrew, Simon , BROWN, Alan, Daniel , DE GROOT, Marcel, John , GAULIER, Steven, Matthieu , LEWTHWAITE, Russell, Andrew , MARSH, Ian, Roger , MILLAN, David, Simon , PEREZ PACHECO, Manuel , RAWSON, David, James , SCIAMMETTA, Nunzio , STORER, Robert, Ian , SWAIN, Nigel, Alan
IPC分类号： C07D213/63 , C07D213/64 , C07D213/65 , C07D213/69 , C07D213/70 , C07D213/74 , C07D213/85 , C07D215/20 , C07D231/56 , C07D239/47 , C07D401/04 , C07D405/12 , C07D487/04 , C07B59/00 , A61K31/44
CPC分类号： C07D213/69 , C07D213/63 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/74 , C07D213/85 , C07D215/20 , C07D231/56 , C07D239/47 , C07D401/04 , C07D405/12 , C07D487/04
摘要： The invention relates to sulfonamide derivatives, to their use i n medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein Het 1 , X, R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.
摘要翻译：本发明涉及磺酰胺衍生物，其药物用途，含有它们的组合物，其制备方法和用于此类方法的中间体。更具体地，本发明涉及式（I）的新的磺酰胺Nav1.7抑制剂：或其药学上可接受的盐，其中Het1，X，R1，R2，R3，R4和R5如说明书中所定义。 Nav 1.7抑制剂可用于治疗各种疾病，特别是疼痛。

5. 发明申请

WO2003092670A1 BOMBESIN ANTAGONISTS 审中-公开
公开(公告)号：WO2003092670A1
公开(公告)日：2003-11-13
申请号：PCT/IB2003/001686
申请日：2003-04-17
申请人： WARNER-LAMBERT COMPANY LLC , HIGGINBOTTOM, Michael , KESTEN, Suzanne, Ross , LEWTHWAITE, Russell, Andrew , PRITCHARD, Martyn, Clive , RAWSON, David, James , SCHELKUN, Robert, Michael , YUEN, Po-Wai
发明人： HIGGINBOTTOM, Michael , KESTEN, Suzanne, Ross , LEWTHWAITE, Russell, Andrew , PRITCHARD, Martyn, Clive , RAWSON, David, James , SCHELKUN, Robert, Michael , YUEN, Po-Wai
IPC分类号： A61K31/17
CPC分类号： C07D207/335 , C07C275/28 , C07C2601/14 , C07D211/26 , C07D213/38 , C07D213/40 , C07D213/56 , C07D213/65 , C07D213/85 , C07D233/64 , C07D235/14 , C07D239/26 , C07D257/04 , C07D277/64 , C07D295/182 , C07D295/185 , C07D309/04 , C07D333/20 , C07D333/58 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： Compounds of formula (I): and their salts, solvates, prodrugs, etc., wherein teh substituents have the values mentioned herein, are bombesin antagonists, which have utility in variety of therapeutic areas including male and female sexual dysfunction, particularly female sexual dysfunction (FSD) especially wherein the FSD is female sexual arousal disorder (FSAD) and male erectile dysfunction (MED).
摘要翻译：式（I）的化合物及其盐，溶剂合物，前药等，其中取代基具有本文提及的值，是铃蟾肽拮抗剂，其可用于多种治疗领域，包括男性和女性性功能障碍，特别是女性性功能障碍（FSD），特别是其中FSD是女性性唤起障碍（FSAD）和男性勃起功能障碍（MED）。

6. 发明申请

WO2006011050A2 PYRIDINE DERIVATIVES 审中-公开
标题翻译：吡啶衍生物
公开(公告)号：WO2006011050A2
公开(公告)日：2006-02-02
申请号：PCT/IB2005/002214
申请日：2005-07-12
申请人： PFIZER LIMITED , PFIZER INC. , LANE, Charlotte, Alice, Louise , MAW, Graham, Nigel , RAWSON, David, James , THOMPSON, Lisa, Rosemary
发明人： LANE, Charlotte, Alice, Louise , MAW, Graham, Nigel , RAWSON, David, James , THOMPSON, Lisa, Rosemary
IPC分类号： C07D213/81 , C07D401/12 , A61K31/44 , A61K31/4439 , A61P29/00
CPC分类号： C07D213/81 , C07D401/12
摘要： The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds for the treatment of pain.
摘要翻译：本发明涉及式（I）化合物及其药学上可接受的盐和溶剂合物，其制备方法，用于制备的中间体和含有这些化合物的组合物以及这些化合物用于治疗疼痛的用途。

7. 发明申请

WO2004039367A1 PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT 审中-公开
标题翻译：具有钙通道ALPHA-2-DELTA子功能的亲和性衍生物
公开(公告)号：WO2004039367A1
公开(公告)日：2004-05-13
申请号：PCT/IB2003/004697
申请日：2003-10-22
申请人： PFIZER LIMITED , PFIZER INC. , RAWSON, David, James
发明人： RAWSON, David, James
IPC分类号： A61K31/401
CPC分类号： C07D207/16 , A61K31/401 , C07D401/12 , C07D405/12
摘要： The compounds of formula (I) or a pharmaceutically acceptable salt, solvate or pro-drug thereof, are proline derivatives useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, fibromyalgia, arthritis, neuropathalogical disorders, sleep disorders, visceral pain disorders and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included. Wherein either X is O, S, NH or CH2 and Y is CH2 or a direct bond, or Y is O, S or NH and X is CH2; and R is a 3-12 membered cycloalkyl, 4-12 membered heterocycloalkyl, heteroaryl or aryl, where any ring may be optionally substituted with one or more substituents independently selected from halogen, hydroxy, cyano, nitro, amino, hydroxycarbonyl, Cl-C6 alkyl, Cl-C6 alkenyl, CI-C6 alkynyl, C l -C 6 alkoxy, hydroxyC,-C 6 alkyl, C l -C 6 alkoxyC,-C 6 alkyl, perfluoro C l -C 6 alkyl, perfluoroC,-C 6 alkoxy, C l -C 6 alkylamino, di- C 1 -C 6 alkylamino, aminoC 1 -C 6 alkyl, C l -C 6 alkylaminoC,-C 6 alkyl, di-Cl-C6 alkylaminoC,-C6 alkyl, CI-C6acyl, C 1 -C 6 acyloxy, C l -C 6 acyloxyC,-C 6 alkyl, C l -C 6 acylamino, C l -C 6 alkylthio, C 1 -C 6 alkylthiocarbonyl, C 1 -C 6 alkylthioxo, C 1 -C 6 alkoxycarbonyl, C l -C 6 alkylsulfonyl, C 1 -C 6 alkylsulfonylamino, aminosulfonyl, C l -C 6 alkylaminosulfonyl, di-C l -C 6 alkylaminosulfonyl, 3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl; or a pharmaceutically acceptable salt, solvate or pro-drug thereof.
摘要翻译：式（I）化合物或其药学上可接受的盐，溶剂化物或前体药物是用于治疗癫痫，眩晕发作，运动功能减退，颅内疾病，神经变性疾病，抑郁症，焦虑症，恐慌症，疼痛，纤维肌痛的脯氨酸衍生物，关节炎，神经病学障碍，睡眠障碍，内脏疼痛障碍和胃肠道疾病。包括用于制备在该方法中有用的最终产物和中间体的方法。还包括含有一种或多种化合物的药物组合物。其中X是O，S，NH或CH 2，Y是CH 2或直接键，或Y是O，S或NH，X是CH 2; R为3-12元环烷基，4-12元杂环烷基，杂芳基或芳基，其中任何环可任选被一个或多个独立地选自卤素，羟基，氰基，硝基，氨基，羟基羰基，C 1 -C 6 烷基，C 1 -C 6烯基，C 1 -C 6炔基，C 1 -C 6烷氧基，羟基C 1 -C 6烷基，C 1 -C 6烷氧基C 1 -C 6烷基，全氟C 1 -C 6烷基，全氟C 1 -C 6烷氧基，C 1 -C 6烷基氨基， -C 1 -C 6烷基氨基，氨基C 1 -C 6烷基，C 1 -C 6烷基氨基C 1 -C 6烷基，C 1 -C 6烷基，C 6烷基，C 1 -C 6酰基，C 1 -C 6酰氧基，C 1 -C 6酰氧基C 1 -C 6烷基，酰基氨基，C 1 -C 6烷硫基，C 1 -C 6烷硫基羰基，C 1 -C 6烷基硫代，C 1 -C 6烷氧基羰基，C 1 -C 6烷基磺酰基，C 1 -C 6烷基磺酰基氨基，氨基磺酰基，C 1 -C 6烷基氨基磺酰基，二-C 1 -C 6烷基氨基磺酰基，3-8元环烷基，4-8元杂环烷基，苯基和单环杂芳基; 或其药学上可接受的盐，溶剂合物或前体药物。

8. 发明申请

WO2002074774A1 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS 审中-公开
标题翻译：环状胍3'，5'-单磷酸酯磷酸酯酶抑制剂
公开(公告)号：WO2002074774A1
公开(公告)日：2002-09-26
申请号：PCT/IB2002/000659
申请日：2002-03-04
申请人： PFIZER LIMITED , PFIZER INC. , DENTON, Stephen, Martin , KEMP, Mark, Ian , NEWMAN, Sandra, Dora , RAWSON, David, James
发明人： DENTON, Stephen, Martin , KEMP, Mark, Ian , NEWMAN, Sandra, Dora , RAWSON, David, James
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： Compound of general formula (I): wherein R 1 , R 2 , R 3 , R 4 , X, Y and R 5 have the meanings given herein which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3',5'-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.
摘要翻译：通式（I）的化合物：其中R 1，R 2，R 3，R 4，X，Y和R 5具有本文给出的用于治疗和预防的含义治疗期望抑制环鸟嘌呤3'，5'-单磷酸磷酸二酯酶（例如cGMP PDE5）的医学病症。

9. 发明申请

WO2004014357A2 THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES 审中-公开
标题翻译：氨基酸衍生物的治疗用途
公开(公告)号：WO2004014357A2
公开(公告)日：2004-02-19
申请号：PCT/IB2003/003193
申请日：2003-07-29
申请人： PFIZER LIMITED , PFIZER INC. , MAW, Graham, Nigel , RAWSON, David, James , THOMPSON, Lisa, Rosemary
发明人： MAW, Graham, Nigel , RAWSON, David, James , THOMPSON, Lisa, Rosemary
IPC分类号： A61K31/195
CPC分类号： C07D271/07 , A61K31/195 , C07C227/22 , C07D209/44 , C07D209/46
摘要： The compounds of formula (I) are useful in the treatment of faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, neuropathic pain, neuropathological disorders and sleep disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.
摘要翻译：式（I）化合物可用于治疗微弱发作，运动功能减退，颅内疾病，神经变性疾病，抑郁症，焦虑症，恐慌症，神经性疼痛，神经病理学障碍和睡眠障碍。包括用于制备在该方法中有用的最终产物和中间体的方法。还包括含有一种或多种化合物的药物组合物。

10. 发明申请

WO2012007868A3 N- SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE - GATED SODIUM CHANNELS 审中-公开
公开(公告)号：WO2012007868A3
公开(公告)日：2012-01-19
申请号：PCT/IB2011/052940
申请日：2011-07-04
申请人： PFIZER LIMITED , BROWN, Alan, Daniel , RAWSON, David, James , STORER, Robert, Ian , SWAIN, Nigel, Alan
发明人： BROWN, Alan, Daniel , RAWSON, David, James , STORER, Robert, Ian , SWAIN, Nigel, Alan
IPC分类号： C07C311/51 , A61K31/18 , A61P25/04
摘要： The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein X, Ar 1 , R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式